The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis

Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mes...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Liang, Yiyi, Li, Shifu, Zeng, Fanyuan, Meng, Yongan, Chen, Ziwei, Liu, Shuang, Tao, Yongguang, Yu, Fenglei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408771/
https://www.ncbi.nlm.nih.gov/pubmed/30849971
http://dx.doi.org/10.1186/s12943-019-0989-z
_version_ 1783401845015707648
author Zhang, Lei
Liang, Yiyi
Li, Shifu
Zeng, Fanyuan
Meng, Yongan
Chen, Ziwei
Liu, Shuang
Tao, Yongguang
Yu, Fenglei
author_facet Zhang, Lei
Liang, Yiyi
Li, Shifu
Zeng, Fanyuan
Meng, Yongan
Chen, Ziwei
Liu, Shuang
Tao, Yongguang
Yu, Fenglei
author_sort Zhang, Lei
collection PubMed
description Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance.
format Online
Article
Text
id pubmed-6408771
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64087712019-03-21 The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis Zhang, Lei Liang, Yiyi Li, Shifu Zeng, Fanyuan Meng, Yongan Chen, Ziwei Liu, Shuang Tao, Yongguang Yu, Fenglei Mol Cancer Review Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance. BioMed Central 2019-03-09 /pmc/articles/PMC6408771/ /pubmed/30849971 http://dx.doi.org/10.1186/s12943-019-0989-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Zhang, Lei
Liang, Yiyi
Li, Shifu
Zeng, Fanyuan
Meng, Yongan
Chen, Ziwei
Liu, Shuang
Tao, Yongguang
Yu, Fenglei
The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title_full The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title_fullStr The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title_full_unstemmed The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title_short The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis
title_sort interplay of circulating tumor dna and chromatin modification, therapeutic resistance, and metastasis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408771/
https://www.ncbi.nlm.nih.gov/pubmed/30849971
http://dx.doi.org/10.1186/s12943-019-0989-z
work_keys_str_mv AT zhanglei theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT liangyiyi theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT lishifu theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT zengfanyuan theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT mengyongan theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT chenziwei theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT liushuang theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT taoyongguang theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT yufenglei theinterplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT zhanglei interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT liangyiyi interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT lishifu interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT zengfanyuan interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT mengyongan interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT chenziwei interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT liushuang interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT taoyongguang interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis
AT yufenglei interplayofcirculatingtumordnaandchromatinmodificationtherapeuticresistanceandmetastasis

Ejemplares similares